COVID 19 is the #1 most commonly reported adverse reaction for OCRELIZUMAB, manufactured by Genentech, Inc.. There are 11,529 FDA adverse event reports linking OCRELIZUMAB to COVID 19. This represents approximately 9.4% of all 123,105 adverse event reports for this drug.
OCRELIZUMAB has an overall safety score of 78 out of 100. Patients taking OCRELIZUMAB who experience covid 19 should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
Reporting Frequency
COVID 1911,529 of 123,105 reports
COVID 19 is moderately reported among OCRELIZUMAB users, representing a notable but not dominant share of adverse events.
Other Side Effects of OCRELIZUMAB
In addition to covid 19, the following adverse reactions have been reported for OCRELIZUMAB:
COVID 19 has been reported as an adverse event in 11,529 FDA reports for OCRELIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
How common is COVID 19 with OCRELIZUMAB?
COVID 19 accounts for approximately 9.4% of all adverse event reports for OCRELIZUMAB, making it one of the most commonly reported side effect.
What should I do if I experience COVID 19 while taking OCRELIZUMAB?
If you experience covid 19 while taking OCRELIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.